Dosage and usage of inclisiran sodium

Inclisiran is a therapeutic drug used to lower low-density lipoprotein cholesterol (LDL-C), particularly in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). Its usage and dosage are relatively clear, aiming to maximize the efficacy of the drug while ensuring patient safety.

1. The recommended initial dose is 284 mg. This dose is usually given as a subcutaneous injection, and after the first injection, patients will receive a second injection three months later. This dosing method is designed to rapidly lower LDL-C levels in the initial stages while allowing time for the patient's body to adapt to the drug. After the second injection, follow-up injections are given every six months to maintain the drug's continued lipid-lowering effects.

2. If the patient misses a regular injection and the next injection is no more than three months away, it is recommended that the patient continue to use Inkslan sodium as originally planned and maintain the established dosing schedule. However, if more than three months are missed, a new dosing schedule will need to be restarted. In this case, the patient would be given an initial dose, followed by a repeat dose three months later, and then every six months thereafter. This approach ensures that patients can return to effective treatment within a reasonable period of time.

3. During the use of Inkslan sodium, doctors will conduct regular assessments based on the patient's clinical status andLDL-C level. In fact, patients' LDL-C levels can be measured within 30 days of starting treatment and at any time thereafter, regardless of the specific timing of dosing. This flexibility allows the medical team to understand the effects of treatment in a timely manner and adjust medication strategies.

4. In terms of medication management, injection of Inkslan sodium should be performed by professional health care personnel. Subcutaneous injections can be given in areas such as the abdomen, upper arms, or thighs, but injections must be avoided in areas with active skin disease or injury, such as sunburn, rash, or obvious inflammation and infection. Before use, be sure to conduct a visual inspection of Inkslan sodium to ensure that the solution is transparent and colorless to light yellow. If any particles or discoloration are observed, discontinue use immediately and seek an alternative.

Reference:https://reference.medscape.com/drug/leqvio-inclisiran-4000063